Acarix Ab · OMXSTO:ACARIX
Acarix Ab — Investor Day (February 2022)
30 slides from Acarix Ab's investor day presentation, Feb 18, 2022
Slide 1: On a mission to enhance the diagnosis of 100 million hearts
On a mission to enhance the diagnosis of 100 million hearts Capital Markets Day Helen Ljungdahl Round CEO February 2022
Slide 2: ACARIX Capital Markets Day
ACARIX Capital Markets Day Feb 18, 2022 1. Introduction to Acarix Helen Ljungdahl Round, CEO 2. Technology Overview Samuel Schmidt, R&D 3. Clinical Experience Clinician and Patient 4. US Expansion Helen Ljungdahl Round, CEO 5. 2021 Financials, Outlook and Plans Christian Lindholm, CFO and CEO 6. Q&A
Slide 3: We all deserve to immediately know if our chest pain is related to heart disease
We all deserve to immediately know if our chest pain is related to heart disease or not
Slide 4: More than 90% of Patients with Chest Pain Undergo Multiple Diagnostic Tests - For No Reason
More than 90% of Patients with Chest Pain Undergo Multiple Diagnostic Tests - For No Reason Every day, approximately 1 million patients consult emergency or primary care for chest pain related symptoms 1 Common symptoms affecting 20 - 40% of the population with chest pains at some point during their
Slide 5: Acarix Leads Paradigm Shift to AI-powered Assessment of CAD
Acarix Leads Paradigm Shift to AI-powered Assessment of CAD Rule-out of CAD in 10 min with 96% confidence The CADScor® System enables non-invasive rule-out of patients with suspected Coronary Artery Disease (CAD) Used on >8,000 patients with suspected CAD With a unique CE- and FDA cleared AI technol
Slide 6: Coronary Artery Disease Assessment in Less than 10 Minutes
Coronary Artery Disease Assessment in Less than 10 Minutes Intended use 1 The intended use of CADScor®System is to record CADScor® heart sounds, i.e., murmurs and vibration for Rule-out 35%1 calculation of a patient specific score, the CAD- score, indicating the risk of coronary stenosis, as Patient
Slide 7: Now Rapidly Expanding to US, Following Early EU Commercial Validation
Installed base, Devices Now Rapidly Expanding to US, 150 Following Early EU Commercial +61% Validation 93 42 100+ CADScor®Systems in commercial use 5 24 CE and FDA De Novo cleared, used in 7 markets including Germany, UK and Sweden, with recurring sales and 85% Gross Margin 2017 2018 2019 2020 2021
Slide 8: Strong Team with Global Experience To Make It All Happen
Strong Team with Global Experience To Make It All Happen Helen Ljungdahl Round Christian Lindholm Anders Krabbe Marianne Solhøj Nørskov Tobias Fritz President and CEO CFO CSMO R&D, Clinical Development CTO Ex Merck, GN, Amnicell Ex TFS International, Doro Ex Novo Nordisk, Ex Novo Nordisk Ex Dignitan
Slide 9: ACARIX Capital Markets Day
ACARIX Capital Markets Day Feb 18, 2022 1. Introduction to Acarix Helen Ljungdahl Round, CEO 2. Technology Overview Samuel Schmidt, R&D 3. Clinical Experience Clinician and Patient 4. US Expansion Helen Ljungdahl Round, CEO 5. 2021 Financials, Outlook and Plans Christian Lindholm, CFO and CEO 6. Q&A
Slide 10: The Idea Behind the CAD-Score
The Idea Behind the CAD-Score Coronary artery disease (CAD) causes week alterations in the heart sounds • Narrowing’s caused by plaque build up will produce turbulent blood flow, which makes a weak noise • The relaxation of the heart is altered by CAD, which changes the heart sounds These sound are
Slide 11: The NOVEL CADScor System
The NOVEL CADScor®System Ultra sensitive and intelligent AI-powered diagnostic aid, rooted in strong Danish audio industry and academia Embed Algorithm Touch sensitive screen Microphone for ambient noise cancelling Sensitive microphone Heart sound recording CAD-score ≤20 CAD-score >20 Low risk of CA
Slide 12: AI Algorithm for Detection of CAD
AI Algorithm for Detection of CAD 0.1 0.05 0 -0.05 -0.1 20 20.5 21 21.5 22 22.5 23 23.5 24 24.5 25 Time (s) Segment the heart sound recording into Noise reduction Feature extraction Classification heart beats 0.3 0.2 CAD-score >20 0.1 SysFRP Elevated risk of CAD FRP 0 HRV -0.1 PCAR Acoustic score -0
Slide 13: The need for rule-out
The need for rule-out Low diagnostic yield of current diagnostic methods Current noninvasive testing includes: • Cardiac CT • Stress ECG • SPECT 90-94% patients undergoing Current noninvasive testing is noninvasive testing • Costly do not suffer • Depends on specialized from CAD 1,2 equipment locate
Slide 14: Rule-out Capacity of CADScor System
Rule-out Capacity of CADScor®System The point-of-care CADScor®System can safely rule out more than one third of patients referred for non-invasive testing with at least 96% certainty 2/3 Non-invasive testing 1/3 No further assessment for CAD Schmidt, S. E., et al. "Coronary artery disease risk recla
Slide 15: A Clinical Powerhouse and Continued Clinical Development
A Clinical Powerhouse and Continued Clinical Development Patients included: • Reported studies: 2,790 • Ongoing studies: ~3,800 Clinical trial overview DAN-NICAD II ADOPT CAD BIO-CAC DAN-NICAD VALIDATE (2018-20) (2012-13) (2014-2015) (2014-16) (2016-17) AKUSTIK (2019-20) N = 228 N = 661 N = 1,675 N=
Slide 16: ACARIX Capital Markets Day
ACARIX Capital Markets Day Feb 18, 2022 1. Introduction to Acarix Helen Ljungdahl Round, CEO 2. Technology Overview Samuel Schmidt, R&D 3. Clinical Experience Clinician and Patient 4. US Expansion Helen Ljungdahl Round, CEO 5. 2021 Financials, Outlook and Plans Christian Lindholm, CFO and CEO 6. Q&A
Slide 17: Testimonials
Testimonials acarix?
Slide 18: ACARIX Capital Markets Day
ACARIX Capital Markets Day Feb 18, 2022 1. Introduction to Acarix Helen Ljungdahl Round, CEO 2. Technology Overview Samuel Schmidt, R&D 3. Clinical Experience Clinician and Patient 4. US Expansion Helen Ljungdahl Round, CEO 5. 2021 Financials, Outlook and Plans Christian Lindholm, CFO and CEO 6. Q&A
Slide 19: The Timing is Right for Acarix to Expand to World's Largest Market
The Timing is Right for Acarix to Expand to World’s Largest Market 18 million chest pain visits to ER / Ambulatory Care annually US Market Fundamentals • US healthcare driving towards Value-based 6-8 million (30-40%) have USD 18 billion in direct costs stable chest pain and for diagnosis (e.g., stre
Slide 20: US Expansion Off to a Good Start
US Expansion Off to a Good Start Sales: Hybrid sales model with direct sales team and commercial partners targeting key states, Integrated Delivery Networks (IDN’s) and Self funded employers' segment Targeting: Primary Care, Internists, and General Cardiologists to enable early diagnostic pathways S
Slide 21: Expansion Into Heart Failure
Expansion Into Heart Failure CAD is most common reason for developing Heart Failure Ability to expand use of CADScor®System to address a broader market More than 60 million have HF; Millions more remain undiagnosed Current methods are difficult to read or too expensive for The rationale monitoring •
Slide 22: ACARIX Capital Markets Day
ACARIX Capital Markets Day Feb 18, 2022 1. Introduction to Acarix Helen Ljungdahl Round, CEO 2. Technology Overview Samuel Schmidt, R&D 3. Clinical Experience Clinician and Patient 4. US Expansion Helen Ljungdahl Round, CEO 5. 2021 Financials, Outlook and Plans Christian Lindholm, CFO and CEO 6. Q&A
Slide 23: Income Statement
Income Statement SEK K FY 2021 FY 2020 Change (%) Revenue 3 760 2 170 73% Gross margin 75% 73% 3% Key Take-aways OPEX 54 519 43 025 27% Revenues increased with 73% for the year EBIT -51 696 -41 431 25% Number of Systems sold 57 51 12% Gross margin increase from 73% to 75% Number of Patches sold 6 88
Slide 24: Financial Position and Cashflow
Financial Position and Cashflow SEK K FY 2021 FY 2020 Change (%) Total assets 118 601 89 948 32% Equity 100 545 70 124 43% Key Take-aways Cash and cash equivalents 15 860 64 113 -75% Increase in total assets and equity driven Cash flow for the period -48 214 10 663 - by ongoing rights issue Complete
Slide 25: Investor Relations (Holding per Jan 31)
Investor Relations (Holding per Jan 31) 10 largest shareholders # Shares Holdings (%) Market value FÖRSÄKRINGSAKTIEBOLAGET, AVANZA PENSION 22 091 397 8,93% 16 789 FORMUE NORD MARKEDSNEUTRAL A/S 6 644 909 2,69% 5 050 Key Take-aways BNY MELLON SA/NV (FORMER BNY), W8IMY 6 524 705 2,64% 4 959 CARNEGIE I
Slide 26: Growth Plans and Objectives 2024
Growth Plans and Objectives 2024 Strong foundation • Technology, evidence, FDA and CE 2024: • > 10,000 patients diagnosed with CADScor® to date • Installed base 3,000 CADScor®Systems • 45 global patents • Target revenue above SEK 200M • Gross Margin above 80% Timing is right • US healthcare moving t
Slide 27: Engage and Invest in Acarix
Engage and Invest in Acarix 1. Solid R&D, patented technology, published clinical data, regulatory approvals Clinical work completed and published. Now ready to scale and drive impact for Acarix, health care providers and patients 2. Strengthened EU position Strong increasing base and increased util
Slide 28: ACARIX Capital Markets Day
ACARIX Capital Markets Day Feb 18, 2022 1. Introduction to Acarix Helen Ljungdahl Round, CEO 2. Technology Overview Samuel Schmidt, R&D 3. Clinical Experience Clinician and Patient 4. US Expansion Helen Ljungdahl Round, CEO 5. 2021 Financials, Outlook and Plans Christian Lindholm, CFO and CEO 6. Q&A
Slide 29: acarix
ae, acarix
Slide 30: Thank you!
Thank you! acarix?